Document Detail

Belatacept utilization recommendations: an expert position.
MedLine Citation:
PMID:  23206310     Owner:  NLM     Status:  MEDLINE    
INTRODUCTION: There is a continuing need for an immunosuppressive therapy that offers a high benefit-risk profile for renal transplant recipients, supporting long-term patient and graft survival while minimizing cumulative nephrotoxicity and other side effects. Belatacept , the first biological agent developed for primary maintenance immunosuppression, was recently approved for use in Europe. Belatacept combined with corticosteroids and a mycophenolic acid is indicated for prophylaxis of graft rejection in adults receiving renal transplant. Its use is contraindicated in Epstein-Barr virus seronegative or serostatus unknown patients due to increased risk of developing posttransplant lymphoproliferative disorder.
AREAS COVERED: This review provides practical recommendations for the use of belatacept, based on safety and efficacy data from Phase II and Phase III clinical trials in de novo kidney transplant recipients.
EXPERT OPINION: Treatment with belatacept is associated with improved long-term graft function, making belatacept an important option for prevention of kidney allograft rejection. Furthermore, efficacy and safety data over several years of therapy suggest that belatacept is particularly suitable for long-term immunosuppression, and the selective targeting offered by belatacept may help avoid some of the non-specific chronic safety risks associated with calcineurin inhibitors and steroids. Future studies will clarify the optimal regimen for belatacept usage.
Josep M Grinyó; Klemens Budde; Franco Citterio; Bernard Charpentier
Publication Detail:
Type:  Journal Article; Review     Date:  2012-12-04
Journal Detail:
Title:  Expert opinion on drug safety     Volume:  12     ISSN:  1744-764X     ISO Abbreviation:  Expert Opin Drug Saf     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2012-12-20     Completed Date:  2013-05-29     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  101163027     Medline TA:  Expert Opin Drug Saf     Country:  England    
Other Details:
Languages:  eng     Pagination:  111-22     Citation Subset:  IM    
Hospital Universitari de Bellvitge, Department of Nephrology, Feixa Llarga, s/n, 08907 Hospitalet de Llobregat, Barcelona, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Graft Rejection / immunology,  prevention & control
Graft Survival / drug effects
Immunoconjugates / administration & dosage,  adverse effects,  therapeutic use*
Immunosuppressive Agents / administration & dosage,  adverse effects,  therapeutic use*
Kidney Transplantation / adverse effects,  immunology*
Patient Selection
Risk Assessment
Risk Factors
Time Factors
Treatment Outcome
Reg. No./Substance:
0/Immunoconjugates; 0/Immunosuppressive Agents; 7D0YB67S97/abatacept

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Exercise training-induced adaptations associated with increases in skeletal muscle glycogen content.
Next Document:  A single group follow-up study of non-surgical patients seen by physiotherapists working in expanded...